Bartomeu Massuti

Bartomeu Massuti

UNVERIFIED PROFILE

Are you Bartomeu Massuti?   Register this Author

Register author
Bartomeu Massuti

Bartomeu Massuti

Publications by authors named "Bartomeu Massuti"

Are you Bartomeu Massuti?   Register this Author

74Publications

2678Reads

43Profile Views

Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors.

Cancer Immunol Immunother 2019 Mar 6;68(3):341-352. Epub 2019 Feb 6.

Lung Cancer Unit, Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-019-02310-2
Publisher Site
http://dx.doi.org/10.1007/s00262-019-02310-2DOI Listing
March 2019

Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.

J Thorac Oncol 2019 Feb 22;14(2):304-310. Epub 2018 Nov 22.

Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute, Barcelona, Spain; Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain; Medical Oncology Service, Hospital General de Valencia, Valencia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.10.168DOI Listing
February 2019

First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).

Eur J Cancer 2017 08 19;81:191-202. Epub 2017 Jun 19.

Maimonides Institute of Biomedical Research, IMIBIC, Spain, Reina Sofía Hospital, University of Córdoba, Spanish Cancer Network, (RTICC), Instituto de Salud Carlos III, Avenida Menéndez Pidal, s/n, ES-14004, Córdoba, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.04.024DOI Listing
August 2017

Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.

J Clin Oncol 2016 May 16;34(13):1476-83. Epub 2016 Feb 16.

Romain Corre and Hervé Léna, Centre Hospitalier Universitaire de Rennes, Rennes; Laurent Greillier, Université de Médecine, Marseille; Hervé Le Caër, Centre Hospitalier de Draguignan, Draguignan; Clarisse Audigier-Valette, Centre Hospitalier Intercommunal de Toulon; Henri Bérard, Hôpital Inter Armées Sainte-Anne, Toulon; Nathalie Baize, Centre Hospitalier Universitaire d'Angers, Angers; Lionel Falchero, Centre Hospitalier de Villefranche sur Saône, Villefranche sur Saône; Isabelle Monnet and Christos Chouaïd, Centre Hospitalier Intercommunal de Créteil, Créteil; Eric Dansin, Centre Oscar Lambret, Lille; Alain Vergnenègre, Centre Hospitalier Universitaire du Cluzeau, Limoges; Marie Marcq, Centre Hospitalier Départemental les Oudairies, La Roche-sur-Yon; Chantal Decroisette, Centre Hospitalier d'Annecy, Annecy; Jean-Bernard Auliac, Centre Hospitalier de Mantes La Jolie, Mantes la Jolie; Suzanna Bota, Centre Hospitalier Universitaire Charles Nicolle, Rouen; Régine Lamy, Centre Hospitalier de Bretagne Sud, Lorient; Cécile Dujon, Hôpital A. Mignot, Le Chesnay; Maurice Pérol, Centre Léon Bérard, Lyon; Jean-Pierre Daurès and Carine Plassot, Université Montpellier 1, Montpellier; Renaud Descourt, Centre Hospitalier Universitaire de Brest, Brest, France; and Bartomeu Massuti, Hospital General Universitario de Alicante, Alicante, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.5839DOI Listing
May 2016

Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.

BMC Cancer 2015 Apr 29;15:327. Epub 2015 Apr 29.

Reina Sofía Hospital, University of Córdoba, Maimonides Institute of Biomedical Research (IMIBIC). Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Córdoba, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1293-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423590PMC
April 2015

ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.

Transl Lung Cancer Res 2014 Jun;3(3):122-30

1 Dr Rosell Oncology Institute, 2 Pangaea Biotech S.L, Quirón Dexeus University Hospital, Barcelona, Spain ; 3 Pivotal CRO, Madrid, Spain ; 4 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 5 Hospital General de Alicante, Alicante, Spain ; 6 CHU Limoges, Limoges, France ; 7 European Institute of Oncology (IEO), Milan, Italy ; 8 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2014.03.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367691PMC
June 2014

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.

Clin Cancer Res 2014 Apr 3;20(7):2001-10. Epub 2014 Feb 3.

Authors' Affiliations: Pangaea Biotech, Barcelona, Spain; Hospital Sant Pau, Barcelona, Spain; Hospital Vall d'Hebron, Barcelona, Spain; Molecular Oncology Research (MORe) Foundation, Barcelona, Spain; Pivotal, Madrid; Hospital General de Alicante, Alicante, Spain; Catalan Institute of Oncology, Badalona, Barcelona, Spain; Complejo Hospitalario Universitario, La Coruña, Spain; Centre François Baclesse, Caen, France; Drum Tower Hospital, Nanjing, China; Kyushu University, Fukuoka, Japan; Cancer Therapeutics Innovation Group, New York, New York, USA; and Helen Diller Comprehensive Cancer Center, University of California, San Francisco, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2233DOI Listing
April 2014

10(th) Congress on Lung Cancer-updates on clinical trials: goal.

Transl Lung Cancer Res 2014 Apr;3(2):66-9

1 Medical Oncology Unit, University Hospital A Coruña, Spain ; 2 Medical Oncology Unit, University Hospital Alicante, Spain ; 3 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Spain ; 4 Pangaea Biotech, USP Dexeus University Institute, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2014.02.05DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367658PMC
April 2014

Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.

Clin Colorectal Cancer 2013 Dec 5;12(4):280-6. Epub 2013 Sep 5.

Medical Oncology Department, HC San Carlos, Madrid, Spain (Center affiliated with the Red Temática de Investigación Cooperativa (RD06/0020/0021), Instituto Carlos III, Spanish Ministry of Science and Innovation, Madrid, Spain). Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2013.06.001DOI Listing
December 2013

Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?

Transl Lung Cancer Res 2013 Jun;2(3):208-21

Breakthrough Cancer Research Unit, Pangaea Biotech S.L, Barcelona, Spain ; ; Catalan Institute of Oncology, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2013.03.06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367596PMC
June 2013

Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer.

Clin Transl Oncol 2012 Aug 11;14(8):592-8. Epub 2012 Jul 11.

Department of Medical Oncology, Institut Català d'Oncologia/IDIBELL, L'Hospitalet de Llobregat, Barcelona, Autovía Castelldefels, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12094-012-0846-7DOI Listing
August 2012

Predicting response to chemotherapy with early-stage lung cancer.

Cancer J 2011 Jan-Feb;17(1):49-56

Medical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e3182091fa3DOI Listing
April 2011

Biomarkers in lung oncology.

Pulm Pharmacol Ther 2010 Dec 13;23(6):508-14. Epub 2010 May 13.

Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pupt.2010.05.003DOI Listing
December 2010

Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer.

Expert Opin Pharmacother 2010 Jul;11(10):1683-93

Hospital Germans Trias i Pujol, Catalan Institute of Oncology, Medical Oncology Service, Ctra Canyet, s/n 08916 Badalona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/14656566.2010.48
Publisher Site
http://dx.doi.org/10.1517/14656566.2010.482101DOI Listing
July 2010

Reflections on the IASLC 12th World Conference on Lung Cancer.

Clin Transl Oncol 2008 Feb;10(2):67-9

View Article

Download full-text PDF

Source
February 2008

The promise of pharmacogenomics: gemcitabine and pemetrexed.

Oncology (Williston Park) 2004 Nov;18(13 Suppl 8):70-6

Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Spain.

View Article

Download full-text PDF

Source
November 2004

Pemetrexed in previously treated non-small-cell lung cancer.

Oncology (Williston Park) 2004 Jul;18(8 Suppl 5):63-71

Medical Oncology Service, Hospital Germans Trias i Pujol, Institut Català d'Oncologia, Badalona (Barcelona), Spain.

View Article

Download full-text PDF

Source
July 2004

Genetic testing for chemotherapy in non-small cell lung cancer.

Lung Cancer 2003 Aug;41 Suppl 1:S97-102

Medical Oncology Service, Hospital Germans Trias i Pujol, Ctra Canyet, s/n, 08916 (Barcelona), Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0169-5002(03)00151-xDOI Listing
August 2003